ADC

12개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved12 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCCurated CoreFDAstaleDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, TDxd)

HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow brea… · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 243Status Approved
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin(RC48) Plus Tratuzumab)

HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 91Status Recruiting
ADCCurated CorestaleSuzhou Suncadia Biopharmaceutic…rezetecanPhase 3

SHR-A1811 (SHR-A1811)

Gastric Cancer; HER2 + Gastric Cancer · HER2

#HER2#ADC#Phase3#BioJungboMoa-pick#Popular+5
Trials 62Status Recruiting
ADCLimited DatastaleDaiichi SankyoDM1) and trastuzumab deruxt…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzmab deruxtecan)

Gastric Cancer; Gastroesophageal Junction (GEJ) Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 56Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Gastric Cancer; Gastrointestinal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#antibody-drug-conjugate#GastricCancer+2
Trials 27Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 10Status Active
ADCLimited DatastaleAstraZenecaPhase 3

Sonesitatug vedotin (Sonesitatug vedotin)

Stomach Neoplasms · Gastric Cancer

#GastricCancer#ADC#Phase3#antibody-drug-conjugate#StomachNeoplasms+2
Trials 6Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy)

Gastric Cancer · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#GastricCancer+1
Trials 2Status Active
ADCLimited DatastaleWest China Second University Ho…Phase 2

MRG003 (Becotatug Vedotin, Becotatug Vedotin (MRG003))

Gastric Cancer; Gastroesophageal Junction (GEJ) Adenocarcinoma · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#GastroesophagealJunctionGEJAdeno+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

HER2-positive Gastric Cancer; Immunotherapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveGastricCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting